Clinical characterization and outcomes of preeclampsia with normal angiogenic profile

References

• ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002;99:159–67
   PubMed Web of Science ®Google Scholar
• Fisher KA, Luger A, Spargo BH, Lindheimer MD. Hypertension in pregnancy: clinical--pathological correlations and remote prognosis. Medicine (Baltimore) 1981;60:267–76
   PubMed Web of Science ®Google Scholar
• Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus 2006;15:148–55
   PubMed Web of Science ®Google Scholar
• Catalano PM. Management of obesity in pregnancy. Obstet Gynecol 2007;109:419–33
   PubMed Web of Science ®Google Scholar
• Powe CE, Thadhani R. Diabetes and the kidney in pregnancy. Semin Nephrol 2011;31:59–69
   PubMed Web of Science ®Google Scholar
• Ihle BU, Long P, Oats J. Early onset pre-eclampsia: recognition of underlying renal disease. Br Med J (Clin Res Ed) 1987;294:79–81
   PubMed Web of Science ®Google Scholar
• Nochy D, Birembaut P, Hinglais N, et al. Renal lesions in the hypertensive syndromes of pregnancy: immunomorphological and ultrastructural studies in 114 cases. Clin Nephrol 1980;13:155–62
   PubMed Web of Science ®Google Scholar
• Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia--eclampsia. Am J Obstet Gynecol 2009;200:481 e1–7
   Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–58
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–83
   PubMed Web of Science ®Google Scholar
• Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021–38
   PubMed Web of Science ®Google Scholar
• Noori M, Donald AE, Angelakopoulou A, et al. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010;122:478–87
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (Placental Growth Factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9–23
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005;17:3–18
   PubMed Web of Science ®Google Scholar
• Lu F, Longo M, Tamayo E, et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 2007;196:396 e1–7; discussion e7
   Web of Science ®Google Scholar
• Li Z, Zhang Y, Ying Ma J, et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007;50:686–92
   PubMed Web of Science ®Google Scholar
• Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA 2011;108:1451–5
   PubMed Web of Science ®Google Scholar
• Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011;124:940–50
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Savasan ZA, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011;24:1187–207
   PubMed Web of Science ®Google Scholar
• Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911–19
   PubMed Web of Science ®Google Scholar
• Moore AG, Young H, Keller JM, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med 2012;25:2651–7
   PubMed Web of Science ®Google Scholar
• Powers RW, Roberts JM, Plymire DA, et al. Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia? Hypertension 2012;60:239–46
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992–1005
   PubMed Web of Science ®Google Scholar
• Perni U, Sison C, Sharma V, et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012;59:740–6
   PubMed Web of Science ®Google Scholar
• Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161 e1–11
   PubMed Web of Science ®Google Scholar
• Stepan H, Schaarschmidt W, Jank A, et al. Use of angiogenic factors (sFlt-1/PlGF ratio) to confirm the diagnosis of preeclampsia in clinical routine: first experience. Z Geburtshilfe Neonatol 2010;214:234–8
   PubMed Web of Science ®Google Scholar
• Verdonk K, Visser W, Russcher H, et al. Differential diagnosis of preeclampsia: remember the soluble fms-like tyrosine kinase 1/placental growth factor ratio. Hypertension 2012;60:884–90
   PubMed Web of Science ®Google Scholar
• Roberts JM, Myatt L, Spong CY, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 2010;362:1282–91
   PubMed Web of Science ®Google Scholar
• Rana S, Cerdeira AS, Wenger J, et al. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One 2012;7:e48259
   PubMed Web of Science ®Google Scholar
• Qazi U, Lam C, Karumanchi SA, Petri M. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol 2008;35:631–4
   PubMed Web of Science ®Google Scholar
• Rolfo A, Attini R, Nuzzo AM, et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 2013;83:177--81
   PubMed Web of Science ®Google Scholar
• Menzies J, Magee LA, Macnab YC, et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy 2007;26:447–62
   PubMed Web of Science ®Google Scholar
• Sheehan HL, Lynch J. Pathology of toxaemia of pregnancy. Baltimore (MA): Williams and Wilkins Co.; 1973
   Google Scholar